CoChat

Impact of KRAS mutations and co-mutations on clinical outcomes in pancreatic ductal adenocarcinoma

Open access

Published version of a preprint

The DOI matches its Crossref record; 75 of the 79 references it cites were found in a registry or an index; 17 of the 68 sources its claims cite were checked for support.

Abstract

The relevance of KRAS mutation alleles to clinical outcome remains inconclusive in pancreatic adenocarcinoma (PDAC). We conducted a retrospective study of 803 patients with PDAC (42% with metastatic disease) at MD Anderson Cancer Center. Overall survival (OS) analysis demonstrated that KRAS mutation status and subtypes were prognostic ( p < 0.001). Relative to patients with KRAS wildtype tumors (median OS 38 months), patients with KRAS G12R had a similar OS (median 34 months), while patients with KRAS Q61 and KRAS G12D mutated tumors had shorter OS (median 20 months [HR: 1.9, 95% CI 1.2–3.0, p = 0.006] and 22 months [HR: 1.7, 95% CI 1.3–2.3, p < 0.001], respectively). There was enrichment of KRAS G12D mutation in metastatic tumors (34% vs 24%, OR: 1.7, 95% CI 1.2–2.4, p = 0.001) and enrichment of KRAS G12R in well and moderately differentiated tumors (14% vs 9%, OR: 1.7, 95% CI 1.05–2.99, p = 0.04). Similar findings were observed in the external validation cohort (PanCAN’s Know Your Tumor® dataset, n = 408).

Overview

CoChat Summary

TL;DR

In a retrospective MD Anderson cohort of 803 patients with pancreatic ductal adenocarcinoma and an external PanCAN Know Your Tumor validation cohort (n = 408), KRAS mutation status and allele subtypes were prognostic for overall survival, with KRASG12R and KRAS wildtype tumors surviving longer than KRASG12D or KRASQ61 tumors. Co-mutations, including ARID1A and SMAD4, and KRAS/TP53/CDKN2A molecular subtypes were also associated with overall survival.

Key findings

  • KRAS mutation status and subtype were prognostic of OS (p < 0.001). Among 703 patients tested for KRAS, 578 (82%) were KRAS-mutant; among KRAS-mutant tumors, KRASG12D was 39%, KRASG12V 31%, KRASG12R 14%, KRASQ61 6%, and other uncommon variants 9%. Median OS was 38 months for KRAS wildtype, 34 months for KRASG12R (HR: 1, 95% CI 0.71–1.5, p = 0.88), 20 months for KRASQ61 (HR: 1.9, 95% CI 1.2–3.0, p = 0.006), and 22 months for KRASG12D (HR: 1.7, 95% CI 1.3–2.3, p < 0.001).
  • KRASG12D was enriched in metastatic stage IV versus localized disease (34% vs 24%, OR: 1.7, 95% CI 1.2–2.4, p = 0.001), and KRASG12R was enriched in well/moderately differentiated versus poorly differentiated/anaplastic tumors (14% vs 9%, OR: 1.7, 95% CI 1.05–2.99, p = 0.04).
  • TP53 was the most frequent KRAS co-mutation (67%), followed by CDKN2A (17%), SMAD4 (11%), and ARID1A (6%). ARID1A mutation was associated with worse OS (median 18 vs 31 months; HR: 1.6, 95% CI 0.99–2.6, p = 0.05), while SMAD4 mutation was associated with better OS (median 35 vs 27 months; HR: 0.67, 95% CI 0.46–0.99, p = 0.046). In metastatic patients with known KRAS, TP53, and CDKN2A status (n = 232), triple-negative tumors had the longest median OS (28 months) and CDKN2A-predominant tumors the worst (12 months; p = 0.014).
  • In the PanCAN KYT validation cohort, KRASG12R was associated with longer median OS (32 months) than KRASQ61 (16 months; HR: 2.6, 95% CI 0.88–7.8, p = 0.02) and KRASG12D (23 months; HR: 1.68, 95% CI 1.06–2.65, p = 0.04).

Methods

  • Retrospective study of 803 patients with PDAC who had tumor tissue somatic mutation testing at MD Anderson Cancer Center (42% with metastatic disease at diagnosis; median age 63 years; 43% female; median follow-up 41 months; median OS 19 months). External validation used PanCAN’s Know Your Tumor dataset (n = 408).
  • Clinical, histopathologic, and molecular data were extracted from the EHR and tumor registry using Palantir Foundry; molecular testing was performed in a CAP-accredited/CLIA-certified laboratory, with gene panels evolving over time. Co-mutation analysis included patients tested with multigene panels (n = 513). KYT samples were sequenced with the Tempus xT NGS panel covering 648 genes.
  • OS was calculated from initial diagnosis to death or last contact; Kaplan–Meier curves and log-rank tests were used, and univariate Cox proportional hazards models estimated HRs. Co-occurrence/mutual exclusivity was assessed with Fisher’s exact test and Benjamini–Hochberg FDR correction (FDR-corrected p < 0.1 significant); two-sided p < 0.05 was considered significant.

Limitations

  • Stated by the paper: heterogeneities in patient populations and tumor mutation testing methods/gene panels; only patients with tissue molecular testing at MD Anderson were included, and patients tested on other panels were excluded; retrospective single tertiary-institution design with ascertainment bias; external validation cohort had limited clinical information and no treatment history; tumor genomic factors may not be the main contributor to allele-specific outcomes; correlative tissue and blood samples were unavailable to evaluate non-genomic factors.
  • Evident from the text: substantial missing data limit interpretation, including stage not available for 59.8%, histology grade for 68.1%, and race/ethnicity for 52.2% of the KYT cohort, with missing data also present in the MD Anderson cohort (e.g., stage 12.7%, grade 18.6%). Rare subtypes were grouped (KRASQ61 variants together; KRASG12C with other uncommon mutations), which may obscure allele-specific effects.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1038/s41698-024-00505-0

Cites

75 of 75 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Fig. 1 Study flowchart diagram. The flowchart shows cohort patient selection. Abbreviations include MD Anderson (MD Anderson Cancer Center).
Fig. 1 Study flowchart diagram. The flowchart shows cohort patient selection. Abbreviations include MD Anderson (MD Anderson Cancer Center).CC BY · PubMed Central
Fig. 2 Overall survival (OS) with KRAS mutations and mutation subtypes. a KM OS curves of all patients, and stage IV patients only b with KRAS-mutated PDAC c Univariate analysis of OS with KRAS mutation subtypes and d Frequencies of different KRAS mutations in patients with KRAS-mutant PDAC (n = 578).
Fig. 2 Overall survival (OS) with KRAS mutations and mutation subtypes. a KM OS curves of all patients, and stage IV patients only b with KRAS-mutated PDAC c Univariate analysis of OS with KRAS mutation subtypes and d Frequencies of different KRAS mutations in patients with KRAS-mutant PDAC (n = 578).CC BY · PubMed Central
Fig. 3 OS with stage and histopathological grade and KRAS mutations. a KM OS curves for tumor stage of our cohort. b KM OS curves for tumor histopathological grade of our cohort. c Bar plot showing enrichment of KRASG12D mutation in metastatic disease. d Bar plot showing enrichment of KRASG12R in well and moderately differentiated tumors.
Fig. 3 OS with stage and histopathological grade and KRAS mutations. a KM OS curves for tumor stage of our cohort. b KM OS curves for tumor histopathological grade of our cohort. c Bar plot showing enrichment of KRASG12D mutation in metastatic disease. d Bar plot showing enrichment of KRASG12R in well and moderately differentiated tumors.CC BY · PubMed Central
Fig. 4 Allele-specific co-mutations with KRAS in the MDA cohort. a Oncoplot showing the distribution of different KRAS mutational subtypes with the different genes in our cohort. b Heatmap showing the co-mutation landscape of the different KRAS mutation subtypes with the different genes and their frequencies. c Bar plot showing the most frequently mutated genes in our cohort.
Fig. 4 Allele-specific co-mutations with KRAS in the MDA cohort. a Oncoplot showing the distribution of different KRAS mutational subtypes with the different genes in our cohort. b Heatmap showing the co-mutation landscape of the different KRAS mutation subtypes with the different genes and their frequencies. c Bar plot showing the most frequently mutated genes in our cohort.CC BY · PubMed Central
Fig. 5 Co-mutation with KRAS and OS analysis of MDA cohort. a Co-mutation analysis of the MD Anderson cohort. Associations between prevalent driver mutations were assessed using Fisher’s exact method and a significant FDR-corrected p indicated by asterixis (*FDR-corrected p < 0.1). b Forest plot showing HR for death (from a univariable analysis) for driver mutations in our cohort, wildtype of each gene was used as reference. c KM OS analysis in patients with metastatic PDAC stratified by molecular subtype.
Fig. 5 Co-mutation with KRAS and OS analysis of MDA cohort. a Co-mutation analysis of the MD Anderson cohort. Associations between prevalent driver mutations were assessed using Fisher’s exact method and a significant FDR-corrected p indicated by asterixis (*FDR-corrected p < 0.1). b Forest plot showing HR for death (from a univariable analysis) for driver mutations in our cohort, wildtype of each gene was used as reference. c KM OS analysis in patients with metastatic PDAC stratified by molecular subtype.CC BY · PubMed Central
Fig. 6 Allele-specific co-mutations with KRAS of KYT cohort. a Oncoplot showing the somatic mutation distribution across the KYT cohort. b Heatmap showing the co-mutation landscape of the different KRAS mutation subtypes with the different genes and their frequencies in KYT cohort.
Fig. 6 Allele-specific co-mutations with KRAS of KYT cohort. a Oncoplot showing the somatic mutation distribution across the KYT cohort. b Heatmap showing the co-mutation landscape of the different KRAS mutation subtypes with the different genes and their frequencies in KYT cohort.CC BY · PubMed Central
Fig. 7 Co-mutation analysis of KYT Cohort with OS. a Co-mutation analysis of KYT cohort, associations between prevalent driver mutations were assessed using the Fisher’s exact method and a significant FDR-corrected p indicated by asterixis (*FDR-corrected p < 0.1). b Bar plot showing the difference in median overall survival between different KRAS mutation subtypes. * indicate p < 0.05 using log-rank test for survival. ^Wildtype: indicate no pathogenic mutations were detected.
Fig. 7 Co-mutation analysis of KYT Cohort with OS. a Co-mutation analysis of KYT cohort, associations between prevalent driver mutations were assessed using the Fisher’s exact method and a significant FDR-corrected p indicated by asterixis (*FDR-corrected p < 0.1). b Bar plot showing the difference in median overall survival between different KRAS mutation subtypes. * indicate p < 0.05 using log-rank test for survival. ^Wildtype: indicate no pathogenic mutations were detected.CC BY · PubMed Central

Verification

Claims the paper makes

10 Valid · 2 Not valid · 28 Not checked · 74 Own results and interpretations

52 more claims

Create a free account to see all 114 claims and to verify the 51 references still open.

See all claims — free account
  • Probably not a substantial claim. 41
  • It may state two separate claims as one. 30

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

2 of 2

Citations

Cites

Show all 75 references

Research works printed but not linked: 1

  1. Govindan, R. et al. Phase 1 study of AMG 510, a novel molecule targeting KRAS G12C mutant solid. Ann. Oncol. 860, v159–v193 (2019).

Cited by

See all 93

Metadata

Authors
Yousef, A., Yousef, M., Chowdhury, S., Abdilleh, K., Knafl, M., Edelkamp, P., Alfaro-Munoz, K., Chacko, R., Peterson, J., Smaglo, B. G., Wolff, R. A., Pant, S., Lee, M. S., Willis, J., Overman, M., Doss, S., Matrisian, L., Hurd, M. W., Snyder, R., Katz, M. H. G., Wang, H., Maitra, A., Shen, J. P., & Zhao, D.
Affiliations
  • The University of Texas MD Anderson Cancer Center (US)
  • Pancreatic Cancer Action Network (US)
Corresponding author
Zhao, Dan
Venue
npj Precision Oncology
Published
2024-02-03
Volume
8
Issue
1
Pages
27-27
ISSN
2397-768X (ISSN-L)
OpenAlex
W4391514138
Cited by
93
References
79
Citations by year
2026: 28 · 2025: 40 · 2024: 25
FWCI
15.92
Type
journal article
Language
en
Open access
Licence
Locations
  • npj Precision Oncology (publishedVersion, cc-by)
  • Research Square (acceptedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • PubMed Central (submittedVersion, cc-by)
  • Digital Commons-TMC (Texas Medical Center) (submittedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
Funders
  • Cancer Prevention and Research Institute of Texas (RR180035)
  • U.S. Department of Health & Human Services | NIH | National Cancer Institute (P30 CA016672)
Topics
  • Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
  • Health Sciences › Medicine › Surgery › Cholangiocarcinoma and Gallbladder Cancer Studies
Keywords
KRAS mutation, pancreatic ductal adenocarcinoma, KRAS G12D, KRAS G12R, prognostic factors, overall survival, metastatic pancreatic cancer, tumor differentiation

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-06, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-06 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (qwen3.8-omni-flash).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Impact of KRAS mutations and co-mutations on clinical outcomes in pancreatic ductal adenocarcinoma. https://app.cochat.ai/papers/10.1038/s41698-024-00505-0
The paper
Yousef, A., Yousef, M., Chowdhury, S., Abdilleh, K., Knafl, M., Edelkamp, P., Alfaro-Munoz, K., Chacko, R., Peterson, J., Smaglo, B. G., Wolff, R. A., Pant, S., Lee, M. S., Willis, J., Overman, M., Doss, S., Matrisian, L., Hurd, M. W., Snyder, R., . . . Zhao, D. (2024). Impact of KRAS mutations and co-mutations on clinical outcomes in pancreatic ductal adenocarcinoma. npj Precision Oncology. https://doi.org/10.1038/s41698-024-00505-0

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.